Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-related toxicity burden. The primary objective of th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Blom, Thomas, Lurvink, Roosmarijn, Aleven, Leonie, Mensink, Maarten, Wolfs, Tom, Dierselhuis, Miranda, van Eijkelenburg, Natasha, Kraal, Kathelijne, van Noesel, Max, van Grotel, Martine, Tytgat, Godelieve
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7925836/
https://ncbi.nlm.nih.gov/pubmed/33680926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.601076
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares